Pharma RSS Digest - 2026-05-02
Overview
Two developments demanded attention this cycle: an FDA Class I recall of Insulet's tubeless insulin pump after nearly 500 serious injuries, and a first-in-class bispecific eye drug advancing to Phase 3 with consistent multi-region data. The Insulet case is a device safety escalation with a silent failure mode; the Kodiak Sciences data reinforces a novel dual-targeting strategy in ocular inflammation where no locally delivered biologic exists yet. Conference-driven news dominated the 48-hour window, with sector coverage tilted toward platform and discovery announcements rather than broad macro shifts.
Key Developments
Insulet Omnipod 5 recall escalated to Class I after 476 serious injuries with zero deaths. The FDA confirmed the most serious classification on April 29, 2026, after a tubing tear in certain pod lots was found to cause insulin under-delivery without triggering any alarm—a silent failure mode that can lead to diabetic ketoacidosis. Insulet began customer outreach in March and expanded the affected lot list in April. Free replacements are available (1-800-641-2049). The recall does not involve CGM components. The silent failure dynamic is the central regulatory concern: patients may not know they are receiving insufficient insulin until complications develop. Watch for injury count updates beyond the April 17 tally and Insulet's execution on the replacement program. (FDA MedWatch)
Kodiak Sciences KSI-101 bispecific advances to Phase 3 with consistent US and Asian cohort data. At the upcoming American Uveitis Society (May 2) and ARVO (May 3–7) meetings, Kodiak will present Phase 1b APEX data showing 58% of Asian MESI patients achieved ≥15-letter BCVA gain and mean improvement of +17.8 letters at Week 24, with central subfield thickness falling below 325 µm after a single injection. In the US cohort, >90% resolved both IRF and SRF by Week 8. The 5 mg and 10 mg dose levels are now advancing into the actively recruiting Phase 3 PEAK and PINNACLE trials. KSI-101 targets both IL-6 and VEGF—a first-in-class locally administered biologic for macular edema secondary to inflammation. The pipeline also includes KSI-102 (dual TNF-α/IL-6) and KSI-103 (IL-1 trap/anti-IL-6), plus an ABCD platform for high-drug-antibody-ratio quarterly dosing. Ocular inflammatory disease is the fourth leading cause of vision loss among working-age adults in developed markets, and no locally delivered biologic is currently approved. Watch for Phase 3 enrollment milestones and whether global data supports parallel regulatory submissions. (PR NewsWire)
Watchlist
Dr. Eric Pierce receives Foundation Fighting Blindness top honor for gene therapy and CRISPR work. The Llura Liggett Gund Award recognizes 25 years of contributions including co-development of LUXTURNA—the first FDA-approved in-vivo gene therapy for an inherited disease—and leading the BRILLIANCE trial, the first in-human CRISPR-Cas9 editing study for CEP290-mediated retinal disease, published in NEJM. Vision improvement was seen in 11 of 14 participants. This is a bellwether award for the inherited retinal disease field and for CRISPR translation more broadly. Watch for further trial durability data and whether the BRILLIANCE approach scales to other CEP290 genotypes or unrelated inherited retinal diseases. (PR NewsWire)
Vanda Pharmaceuticals launches NEREUS (tradipitant), the first new prescription motion sickness drug in over 40 years. Approved December 30, 2025, the selective NK-1 receptor antagonist is now commercially available at $85 per dose ($255 list price) via nereus.us and retail pharmacies. The Phase 3 Motion Syros and Motion Serifos sea trials demonstrated statistically significant vomiting prevention versus placebo. An estimated 65–78 million Americans suffer from motion sickness, representing a large underserved market. The drug carries drowsiness warnings and potential impairment of driving or operating machinery. Watch for prescription uptake, insurance reimbursement decisions, and whether real-world effectiveness in diverse conditions (air, land, virtual reality) matches sea-trial conditions. (PR NewsWire)
Community Healthcare Trust increases Q1 2026 dividend to $0.48 per share. The healthcare REIT's board approved the dividend on April 30, payable May 22 to shareholders of record May 11. The annualized rate is now $1.92 per share. The company has raised its dividend every quarter since its IPO. Community Healthcare Trust focuses on outpatient healthcare real estate—a defensive sub-sector with stable tenant revenues. Watch for occupancy trends and any changes in tenant concentration. (PR NewsWire)